EPISODE · Apr 28, 2026 · 2 MIN
Ocular Myasthenia Gravis Gets Its First Targeted Biologic Candidate
from TheBrief.Health · host TheBrief.Health
New Phase 3 data highlight efgartigimod’s targeted efficacy in ocular myasthenia gravis, signaling a shift toward precision therapies that reduce treatment burden and improve patient-centered outcomes.
What this episode covers
New Phase 3 data highlight efgartigimod’s targeted efficacy in ocular myasthenia gravis, signaling a shift toward precision therapies that reduce treatment burden and improve patient-centered outcomes.
NOW PLAYING
Ocular Myasthenia Gravis Gets Its First Targeted Biologic Candidate
No transcript for this episode yet
Similar Episodes
Apr 21, 2026 ·13m
Apr 19, 2026 ·16m
Apr 17, 2026 ·13m
Apr 13, 2026 ·11m
Apr 11, 2026 ·16m